YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
[Wall Street New York City] aluxum/E+ via Getty Images Here's a quick look at the stocks that are seeing gap-up moves before the bell on Friday. Stock index futures were higher on Friday while Treasury yields fell as investors focused on t…
* Prime Medicine (PRME [https://seekingalpha.com/symbol/PRME]) shares jumped 8% Friday after the FDA cleared its IND application for PM647, an experimental gene-editing therapy for Alpha-1 Antitrypsin Deficiency. * The clearance allows Pri…
Prime Drink Group Corp. MONTREAL, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) ("Prime" or the "Company") announces that further to its news releases dated July 30, August 14, August 27 and September 10, 2026, the…
This article first appeared on GuruFocus. Gene-editing stocks fell Wednesday after Anthropic's Claude AI model identified an enzyme system with characteristics similar to technology used to alter DNA. Beam Therapeutics (BEAM), CRISPR Thera…
Company Logo The global in vivo gene editing market was valued at USD 3.4 billion in 2025 and is forecast to reach USD 22.6 billion by 2036, growing at a 16.8% CAGR from 2026. Growth is driven by CRISPR, base and prime editing, LNP and AAV…
Prime Drink Group Corp. MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) ("Prime" or the "Company") announces that further to its news releases dated July 30, August 14 and August 27, 2026, the Company volun…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
[US 100 dollar bill folded into an up arrow on wooden table. Illustration of the concept of inflation, profit, earning and investment] Biotech stocks have reached their highest level since the height of the pandemic after Moderna (MRNA [ht…
Prime Medicine, Inc. -- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable ar…
Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can halve the risk of heart attacks and strokes…
Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report.…
SpaceX (SPCX) investors are reeling after a brutal sell-off. The stock has comfortably slipped below its $135 IPO price, according to Yahoo Finance, facing concerns over Starship delays, an incredibly rich valuation, and a major post-earni…
Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patie…
Cathie Wood, CEO of Ark Investment Management, is known for buying high-growth stocks soon after they go public, especially when share prices pull back after an early rally. That's exactly what she's doing with SpaceX this week, adding mor…
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM), following a fav…
Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously disclosed arbitration with Beam Therape…
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52…
This article first appeared on GuruFocus. Cathie Wood's ARK added to its Meta Platforms (NASDAQ:META) position while further reducing its stake in Advanced Micro Devices (NASDAQ:AMD), according to the firm's daily trade disclosure released…
In late June 2026, an arbitration tribunal ruled that Prime Medicine did not breach its 2019 collaboration agreement with Beam Therapeutics and can continue developing PM647, an investigational gene-editing therapy for Alpha-1 Antitrypsin…
Cathie Wood, head of Ark Investment Management, is known for buying her favorite tech stocks during market pullbacks. That's exactly what she just did, adding shares of an AI stock after a sharp selloff. In 2025, the flagship Ark Innovatio…
Prime Medicine won a legal battle with Beam Therapeutics on Wednesday. Prime shares jumped while Beam stock skidded. Continue Reading
[Genetic engineering] Andy/iStock via Getty Images Prime Medicine (PRME [https://seekingalpha.com/symbol/PRME]) added ~8% in the premarket on Wednesday after an arbitration tribunal sided with the gene editing company in connection with a…
Prime Medicine, Inc. -- Arbitration tribunal declared that PM647 is within Prime Medicine's "Field", confirming Prime Medicine's right to develop and commercialize PM647 in AATD -- -- Prime Medicine owes no monetary damages to Beam Therape…
Prime Medicine, Inc. (NASDAQ:PRME) ranks among the overlooked penny stocks to buy right now, supported by strong upside potential. Multiple regulatory clearances across its gene-editing pipeline are prompting analysts to turn more construc…
Ocular Therapeutix (NASDAQ:OCUL) and Prime Medicine (NASDAQ:PRME) represent two distinct paths within the high-risk, high-reward world of medical innovation. Choosing between them requires balancing established commercial revenue against m…
MONTRÉAL, 12 juin 2026 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce qu’elle procédera à un placement privé d'unités de la Société (les « unités ») sans l'entremise d'un courtier, afin de l…
MONTREAL, June 12, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it is proceeding with a non-brokered private placement offering of units of the Company (the “Units”) to raise minimu…
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for…
Prime Medicine, Inc. (NASDAQ:PRME) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 15, 2026, Prime Medicine, Inc. (NASDAQ:PRME) announced the appointment of Svetlana Makhni as Chief Financial Officer. In this role, sh…
MONTRÉAL, 14 avr. 2026 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») annonce un placement privé sans l’entremise d’un courtier (le « placement ») visant l’émission d’un minimum de 10 unités (chacun…
MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a non-brokered private placement (the “Private Placement”) of a minimum of 10 units (each, a “Unit”) and a maximum of 16…
Prime Medicine Inc. (NASDAQ:PRME) is one of the best new penny stocks to buy. On March 3, Prime Medicine reported its full-year 2025 financial results, highlighting a shift toward its in vivo liver franchise. The company ended the year wit…
MONTRÉAL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce the appointment of Germain Turpin as Interim President and Chief Executive Officer of the Company. Mr. Turpin…
MONTRÉAL, 27 févr. 2026 (GLOBE NEWSWIRE) -- Groupe Prime Drink Corp. (CSE : PRME) (« Prime » ou la « Société ») est heureuse d’annoncer la nomination de Germain Turpin à titre de président et chef de la direction par intérim de la Société.…